VEGFA and breast carcinoma: However, other breast cancer therapies that can affect the CV system include alkylating agents (e.g., cyclophosphamide), VEGF inhibitors (e.g., bevacizumab), tyrosine kinase inhibitors (e.g., lapatinib, neratinib), antimicrotubular agents (e.g., paclitaxel, docetaxel), antimetabolites (e.g., fluorouracil, capecitabine) and hormone therapies including cyclin-dependent kinases (CDK) 4/6 inhibitors (e.g., palbociclib, ribociclib, abemaciclib) [16].